Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6522)
All Articles published online
|
Publishing Process of This Article
|
Dec 14, 2016 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(46): 10124-10130 [PMID: 28028360 DOI: 10.3748/wjg.v22.i46.10124] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v22/i46/10124.htm |
| Number | Citing Articles |
| 1 |
Pan Liu, Jiarui Feng, Meng Sun, Wen Yuan, Ruijing Xiao, Jie Xiong, Xiaoxin Huang, Meng Xiong, Wu Chen, Xin Yu, Qian Sun, Xiaojie Zhao, Qiuping Zhang, Liang Shao. Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells. International Journal of Oncology 2017; 51(6): 1878 doi: 10.3892/ijo.2017.4153
|
| 2 |
Zainab L Rai, Veronica Ranieri, Daniel H Palmer, Peter Littler, Pauleh Ghaneh, Kurinchi Gurusamy, Derek Manas, Elena Pizzo, Eftychia Eirini Psarelli, Roopinder Gilmore, Praveen Peddu, David C Bartlett, Nicola de Liguori Carino, Brian R Davidson. Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial. BMJ Open 2022; 12(5): e050166 doi: 10.1136/bmjopen-2021-050166
|
| 3 |
Ana Fernández, Mercedes Salgado, Adelaida García, Elvira Buxò, Ruth Vera, Jorge Adeva, Paula Jiménez-Fonseca, Guillermo Quintero, Cristina Llorca, Mamen Cañabate, Luis Jesús López, Andrés Muñoz, Patricia Ramírez, Paula González, Carlos López, Margarita Reboredo, Elena Gallardo, Manuel Sanchez-Cánovas, Javier Gallego, Carmen Guillén, Nuria Ruiz-Miravet, Víctor Navarro-Pérez, Juan De la Cámara, Inmaculada Alés-Díaz, Roberto Antonio Pazo-Cid, Alberto Carmona-Bayonas. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-5101-3
|
| 4 |
Alex Cazes, Oscar Betancourt, Edgar Esparza, Evangeline S. Mose, Dawn Jaquish, Eric Wong, Alexis A. Wascher, Hervé Tiriac, Marco Gymnopoulos, Andrew M. Lowy. A MET Targeting Antibody–Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer. Clinical Cancer Research 2021; 27(7): 2100 doi: 10.1158/1078-0432.CCR-20-3210
|
| 5 |
Li-Lian Gan, Ling-Wei Hii, Shew-Fung Wong, Chee-Onn Leong, Chun-Wai Mai. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers 2020; 12(7): 1872 doi: 10.3390/cancers12071872
|
| 6 |
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi. NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?. Future Oncology 2023; 19(9): 617 doi: 10.2217/fon-2023-0088
|
| 7 |
Hamid Bakshi, Mazhar Zoubi, Hakkim Faruck, Alaa Aljabali, Firas Rabi, Amin Hafiz, Khalid Al-Batanyeh, Bahaa Al-Trad, Prawej Ansari, Mohamed Nasef, Nitin Charbe, Saurabh Satija, Meenu Mehta, Vijay Mishra, Gaurav Gupta, Salem Abobaker, Poonam Negi, Ibrahim Azzouz, Ashref Dardouri, Harish Dureja, Parteek Prasher, Dinesh Chellappan, Kamal Dua, Mateus Webba da Silva, Mohamed Tanani, Paul McCarron, Murtaza Tambuwala. Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage. Nutrients 2020; 12(6): 1901 doi: 10.3390/nu12061901
|
| 8 |
Umme Hani, Riyaz Ali M. Osmani, Ayesha Siddiqua, Shadma Wahab, Sadia Batool, Hissana Ather, Norhan Sheraba, Ali Alqahtani. A systematic study of novel drug delivery mechanisms and treatment strategies for pancreatic cancer. Journal of Drug Delivery Science and Technology 2021; 63: 102539 doi: 10.1016/j.jddst.2021.102539
|
| 9 |
Daniel Brock Hewitt, Nicholas Nissen, Hassan Hatoum, Benjamin Musher, John Seng, Andrew L. Coveler, Raed Al-Rajabi, Charles J. Yeo, Benjamin Leiby, Joshua Banks, Lodovico Balducci, Gina Vaccaro, Noelle LoConte, Thomas J. George, Warren Brenner, Emad Elquza, Nicholas Vahanian, Gabriela Rossi, Eugene Kennedy, Charles Link, Harish Lavu. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Annals of Surgery 2022; 275(1): 45 doi: 10.1097/SLA.0000000000004669
|
| 10 |
Karl R. Aigner, Sabine Gailhofer, Emir Selak, Kornelia Aigner. Intra-arterial infusion chemotherapy versus isolated upper abdominal perfusion for advanced pancreatic cancer: a retrospective cohort study on 454 patients. Journal of Cancer Research and Clinical Oncology 2019; 145(11): 2855 doi: 10.1007/s00432-019-03019-6
|
| 11 |
Daheui Choi, Alan M. Gonzalez‐Suarez, Mihai G. Dumbrava, Michael Medlyn, Jose M. de Hoyos‐Vega, Frank Cichocki, Jeffrey S. Miller, Li Ding, Mojun Zhu, Gulnaz Stybayeva, Alexandre Gaspar‐Maia, Daniel D. Billadeau, Wen Wee Ma, Alexander Revzin. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy. Advanced Science 2024; 11(5) doi: 10.1002/advs.202303088
|
| 12 |
Daria R. Q. de Almeida, Ancély F. dos Santos, Rosangela A. M. Wailemann, Letícia F. Terra, Vinícius M. Gomes, Gabriel S. Arini, Ester R. M. Bertoldi, Eduardo M. Reis, Maurício S. Baptista, Leticia Labriola. Necroptosis activation is associated with greater methylene blue-photodynamic therapy-induced cytotoxicity in human pancreatic ductal adenocarcinoma cells. Photochemical & Photobiological Sciences 2022; 22(4): 729 doi: 10.1007/s43630-022-00347-4
|
| 13 |
Hui Shan Liew, Chun-Wai Mai, Mohd Zulkefeli, Thiagarajan Madheswaran, Lik Voon Kiew, Lesley Jia Wei Pua, Ling Wei Hii, Wei Meng Lim, May Lee Low. Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.903210
|
| 14 |
Leva Hajatdoost, Keyvan Sedaghat, Erin Walker, Jackson Thomas, Sam Kosari. Chemotherapy in Pancreatic Cancer: A Systematic Review. Medicina 2018; 54(3): 48 doi: 10.3390/medicina54030048
|
| 15 |
Adam R. Wolfe, Dhivya Prabhakar, Vedat O. Yildiz, Jordan M. Cloyd, Mary Dillhoff, Laith Abushahin, Dayssy Alexandra Diaz, Eric D. Miller, Wei Chen, Wendy L. Frankel, Anne Noonan, Terence M. Williams. Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Medicine 2020; 9(13): 4711 doi: 10.1002/cam4.3075
|
| 16 |
Zahra S. Razaee, Galen Cook‐Wiens, Mourad Tighiouart. A nonparametric Bayesian method for dose finding in drug combinations cancer trials. Statistics in Medicine 2022; 41(6): 1059 doi: 10.1002/sim.9316
|
| 17 |
Junko Tahara, Kyoko Shimizu, Nao Otsuka, Junichi Akao, Yukiko Takayama, Katsutoshi Tokushige. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 2018; 82(2): 245 doi: 10.1007/s00280-018-3611-y
|
| 18 |
Huiqin Liu, Mengnan Sun, Zhengsheng Liu, Chao Kong, Weijian Kong, Junxiao Ye, Jianan Gong, David C.S. Huang, Feng Qian. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. Journal of Controlled Release 2019; 296: 40 doi: 10.1016/j.jconrel.2019.01.014
|
| 19 |
Rebecca Ibrahim, Rita Khoury, Tony Ibrahim, Tarek Assi, Axel Le Cesne. KRAS G12C mutation: from black sheep to key player in pancreatic cancer treatment. Future Oncology 2023; 19(7): 485 doi: 10.2217/fon-2023-0067
|
| 20 |
Julien Péron, Joris Giai, Delphine Maucort-Boulch, Marc Buyse. The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. Pancreas 2019; 48(2): 275 doi: 10.1097/MPA.0000000000001234
|
| 21 |
Shivang Dhoundiyal, Md. Aftab Alam. Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic
Cancer using Nanotechnology. Current Cancer Drug Targets 2023; 23(9): 697 doi: 10.2174/1568009623666230329085618
|
| 22 |
Melika Rezaee, Jing Wang, Mehdi Razavi, Gang Ren, Fengyan Zheng, Ahmed Hussein, Mujib Ullah, Avnesh S. Thakor. A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-52490-1
|
| 23 |
Guillermo Urrutia, Ann Salmonson, Jorge Toro-Zapata, Thiago M. de Assuncao, Angela Mathison, Nelson Dusetti, Juan Iovanna, Raul Urrutia, Gwen Lomberk. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. Molecular Cancer Research 2020; 18(3): 448 doi: 10.1158/1541-7786.MCR-19-0490
|
| 24 |
Benjamin B. Kasten, Abhishek Gangrade, Harrison Kim, Jinda Fan, Soldano Ferrone, Cristina R. Ferrone, Kurt R. Zinn, Donald J. Buchsbaum. 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nuclear Medicine and Biology 2018; 58: 67 doi: 10.1016/j.nucmedbio.2017.12.004
|
| 25 |
Dimitrios C. Ziogas, Eirini Papadopoulou, Helen Gogas, Stratigoula Sakellariou, Evangellos Felekouras, Charalampos Theocharopoulos, Dimitra T. Stefanou, Maria Theochari, Ioannis Boukovinas, Dimitris Matthaios, Anna Koumarianou, Eleni Zairi, Michalis Liontos, Konstantinos Koutsoukos, Vasiliki Metaxa-Mariatou, George Kapetsis, Angeliki Meintani, Georgios N. Tsaousis, George Nasioulas. Digging into the NGS Information from a Large-Scale South European Population with Metastatic/Unresectable Pancreatic Ductal Adenocarcinoma: A Real-World Genomic Depiction. Cancers 2023; 16(1): 2 doi: 10.3390/cancers16010002
|